-The Biocon India group promoter of Biocon India Ltd. Ms Kiran
Mazumdar Shaw, Chairman and Managing Director of Biocon India Group.
-Biocon India appointed DSP Merrill Lynch and Kotak Mahindra for its
Rs 150-crore IPO scheduled for June next year. Biocon-Shantha
Biotech, the 50:50 joint venture between Biocon India and Shantha
Biotechnics, focuses on the domestic and global human insulin markets
by maximizing on R&D manufacturing and regulatory capacities of the
-ICICI Venture offloads 10-pc stake in Biocon
-Clinigene International inaugurates human pharmacology unit for
-Comes out with an Initial Public Offering (IPO) of 10 million shares
at a price of Rs 315 per share for a face value of Rs 5 per share
which constitutes 10% of the post-issue capital (Rs 100 crore),
listed at Rs 425
-Biocon Ltd has entered into a nine-year export contract with US
major Bristol-Myers Squibb Co to supply the bulk form of its
recombinant human insulin
-Biocon forays into lifestyle drugs market
-Biocon's clinical research arm, Clinigene International Pvt Ltd.
re-accredited by the College of American Pathologists (CAP) following
a recent inspection
-Biocon Ltd has informed that in an unusual commercial transaction
between Cuba and USA, a Californian Biotechnology Company, CancerVax
Corporation received a rare US Government approval to License three
experimental cancer drugs from a leading Cuban Institute (CIMAB)
-Biocon said on July 26 that its Cuban partner CIMAB (Centre for
Molecular Immunology) in the joint venture with Biocon
Biopharmaceuticals will be able to license out three experimental
cancer drugs to a Californian Biotechnology company, CancerVax
-Biocon, Syngene enters into Research Agreement with Novartis
Institutes for Biomedical Research Inc
-Biocon unveils new bio insulin
Biocon signs MoU with Karolinska Institute.
-Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, has been honoured with
the Corporate Leadership Award 2005 of the American India Foundation
-Biocon signs Licensing agreement with Bentley Pharmaceuticals Inc.
-Biocon ties up with ICICI Prudential Life Insurance
-Biocon concludes Phase-IV trials of Insugem
-Biocon Ltd and Abu Dhabi based pharmaceutical company Neopharma have
signed an MOU to establish a JV to manufacture and market a range of
Bio-pharmaceuticals for the GCC countries (Gulf Cooperation
-Biocon Ltd on March 14, 2007 has announced that its subsidiary
Company Syngene has entered into a research partnership with
-Biocon signs MOU with Neopharma for a JV
-The Company has issued Bonus Shares in the Ratio of 1:1.
- Biocon and Amylin Pharmaceuitcals Inc have entered into an
exclusive agreement to jointly develop, commercialise and manufacture
a new peptide therapeutic for potential treatment of diabetes. The two
companies will share development costs.
-Biocon launches BASALOG - long lasting basal insulin for Type 1 &
Type 2 Diabetics
-Biocon joins hands with Amylin Pharmaceuticals
-Biocon inks partnership with ISB to launch the Biocon Cell for
- Biocon has launched its new 'comprehensive care' division,
dedicated to provide affordable solutions to critical illnesses such
as nosocomial infections, post surgical complications, trauma and
- Biocon has signed an agreement with Teleradiology Solutions to
provide teleradiology reporting services to Clinigene, Biocon's
clinical research arm.
-Biocon announces preliminary data on its novel oral insulin drug
-Biocon announces project commencement for first high-end
biopharmaceutical manufacturing and R&D facility in Bio-XCell,
-Biocon launches INSUPen®, a convenient and affordable reusable
insulin delivery device
-Clinigene International Enters into Collaborative Clinical Research
-Biocon wins Biospectrum BioPharma Company of the year award
-Biocon wins Best Design and Information Award for the Healthcare
Sector at Bangalore India Bio
-Biocon wins Excellence in Environmental Management Award
-Biocon wins Best Exhibitor Award in the category of Biocontent and
Information at Bangalore India Bio
-Biocon wins Golden Peacock National Quality Award
-Biocon Research Centre Inaugurated by Nobel Laureate Prof Kurt
-Biocon announces that it has entered into an option agreement with
Bristol-Myers Squibb for
Biocon’s IN-105, an oral insulin drug candidate
-Biocon Launches ALZUMAb - a First in Class Novel Biologic Treatment
for Psoriasis Patients in India.
-Biocon Enhances Partnership with Mylan through Strategic
Collaboration for Insulin Products.
-Biocon Partners with CytoSorbents to Market CytoSorb®-A
First-in-Class Therapy for Sepsis Management.
-Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the
-Biocon the Top Ten Most Admired Companies in the Pharma & Healthcare
-Biocon wins Best Design and Innovation Exhibitor Award at Bangalore
-Biocon has been conferred with the Sir J C Bose Memorial Award 2013
(Institutional category) by Indian Science Monitor (ISM) for its
contribution in the field of Biotechnology, with special reference to
the launch of ALZUMAb (Itolizumab).
-Biocon Foundation gets 'Asia Best CSR Practices Award 2014 for
''Cervical Cancer Screening Programme''.
-Biocon wins Thomson Reuters India Innovation Awards 2014
-Biocon launches drug for breast cancer treatment
-Biocon partners with Advaxis for novel cancer immunotherapy
-Biocon launches flagship program in collaboration with KGI